Nautilus Biotech Narrows Q3 Loss Amidst Reduced R&D Spend

TL;DR

**NAUT is burning cash, but slowing the burn; watch for platform progress or expect more dilution.**

AI Summary

Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $13.574 million for the three months ended September 30, 2025, an improvement from a net loss of $16.446 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $45.220 million, compared to $53.186 million in 2024. Total operating expenses decreased to $15.472 million for the three months ended September 30, 2025, down from $19.100 million in 2024, primarily due to reduced research and development expenses of $9.605 million (down from $12.288 million) and general and administrative expenses of $5.867 million (down from $6.812 million). The company's cash, cash equivalents, and short-term investments stood at $131.4 million as of September 30, 2025, a decrease from $132.826 million at December 31, 2024. Long-term investments also saw a significant reduction from $76.405 million to $37.059 million. The company continues to operate at a net loss and negative cash flows from operations, with an accumulated deficit of $318.2 million as of September 30, 2025, but believes its current cash resources will fund operations for at least the next twelve months.

Why It Matters

Nautilus Biotechnology's continued net losses and reliance on existing cash reserves for future operations signal a critical period for investors. While the reduction in operating expenses, particularly R&D, has helped narrow losses, it raises questions about the pace of development for its proteomics platform, which remains in the development stage. For employees, sustained losses could imply future operational adjustments. Customers and the broader market are keenly watching for the commercialization of the Nautilus platform, which could disrupt the proteomics field, but delays or funding issues could impact its competitive positioning against established players or other emerging biotech firms.

Risk Assessment

Risk Level: high — Nautilus Biotechnology has an accumulated deficit of $318.2 million as of September 30, 2025, and has incurred net operating losses and negative cash flows from operations every year since inception. While the company believes its $131.4 million in cash, cash equivalents, and short-term investments will fund operations for at least the next twelve months, its long-term viability is highly dependent on the successful development and commercialization of its proteomics platform, which is still in the development stage.

Analyst Insight

Investors should closely monitor Nautilus Biotechnology's progress in commercializing its proteomics platform and its cash burn rate. Given the high-risk profile and ongoing losses, consider this a speculative investment. Await concrete milestones in platform development or strategic partnerships before increasing exposure.

Financial Highlights

total Assets

$200.915M

net Income

-$13.574M

eps

-$0.11

cash Position

$131.4M

Key Numbers

• $13.574M — Net Loss (Q3 2025) (Improved from $16.446M in Q3 2024)
• $45.220M — Net Loss (YTD Sept 2025) (Improved from $53.186M in YTD Sept 2024)
• $15.472M — Total Operating Expenses (Q3 2025) (Decreased from $19.100M in Q3 2024)
• $9.605M — Research & Development Expenses (Q3 2025) (Decreased from $12.288M in Q3 2024)
• $131.4M — Cash & Short-term Investments (Sept 30, 2025) (Sufficient for at least next 12 months of operations)
• $318.2M — Accumulated Deficit (Sept 30, 2025) (Indicates significant historical losses)
• $38.321M — Net Cash Used in Operating Activities (YTD Sept 2025) (Reduced from $44.836M in YTD Sept 2024)
• 126,305,122 — Shares Outstanding (Oct 23, 2025) (Reflects slight increase from 126,106,176 at Dec 31, 2024)

Key Players & Entities

• Nautilus Biotechnology, Inc. (company) — registrant
• $13.574 million (dollar_amount) — net loss for Q3 2025
• $16.446 million (dollar_amount) — net loss for Q3 2024
• $45.220 million (dollar_amount) — net loss for nine months ended Sept 30, 2025
• $53.186 million (dollar_amount) — net loss for nine months ended Sept 30, 2024
• $15.472 million (dollar_amount) — total operating expenses for Q3 2025
• $19.100 million (dollar_amount) — total operating expenses for Q3 2024
• $9.605 million (dollar_amount) — research and development expenses for Q3 2025
• $12.288 million (dollar_amount) — research and development expenses for Q3 2024
• $131.4 million (dollar_amount) — cash, cash equivalents, and short-term investments as of Sept 30, 2025

FAQ

Risk Factors

• Sustained Net Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $13.574 million for Q3 2025 and $45.220 million year-to-date, contributing to an accumulated deficit of $318.2 million as of September 30, 2025. This indicates a history of operating at a loss, which raises concerns about long-term financial sustainability.
• Declining Cash and Investment Balances [medium — financial]: Total cash, cash equivalents, and short-term investments decreased to $131.4 million as of September 30, 2025, from $132.826 million at the end of 2024. Furthermore, long-term investments saw a substantial reduction from $76.405 million to $37.059 million, potentially impacting future strategic flexibility.
• Dependence on Future Funding [high — operational]: Despite management's belief that current cash resources will fund operations for at least the next twelve months, the company continues to operate with negative cash flows from operations. Any unforeseen delays in achieving profitability or securing additional funding could pose a significant risk.
• Reduction in R&D Spending [medium — operational]: Research and development expenses decreased to $9.605 million in Q3 2025 from $12.288 million in Q3 2024. While this contributed to reduced overall expenses, a sustained decrease in R&D could impact the company's ability to innovate and maintain its competitive edge in the biotechnology sector.
• Biotechnology Sector Regulatory Environment [medium — regulatory]: As a biotechnology company, Nautilus is subject to stringent regulatory oversight from bodies like the FDA. Changes in regulations, delays in approvals, or failure to comply with evolving standards can significantly impact product development timelines and market access.
• Competitive Landscape [medium — market]: The biotechnology industry is highly competitive, with numerous companies vying for market share and scientific advancement. Nautilus faces competition from established players and emerging startups, requiring continuous innovation and effective commercialization strategies.

Industry Context

Nautilus Biotechnology operates in the highly competitive and rapidly evolving biotechnology sector. The industry is characterized by significant investment in research and development, long product development cycles, and stringent regulatory hurdles. Companies like Nautilus focus on developing novel technologies for biological analysis, aiming to disrupt traditional methods and accelerate scientific discovery.

Regulatory Implications

As a biotechnology firm, Nautilus is subject to rigorous regulatory scrutiny, particularly from the FDA, concerning its technology and potential applications. Compliance with evolving standards and successful navigation of the approval processes are critical. Any missteps in regulatory compliance or delays in approvals could significantly hinder market entry and commercialization efforts.

What Investors Should Do

1. Monitor R&D spending trends: While expense reduction is positive, a sustained decline in R&D could signal a slowdown in innovation. Investors should watch for strategic investments in future growth areas.
2. Assess cash burn rate and runway: The company has $131.4 million in cash, but continues to burn cash. Investors should evaluate the sustainability of operations and the potential need for future capital raises.
3. Track progress towards commercialization: Investors should look for updates on the development and potential market adoption of Nautilus's core technologies, as this is key to achieving profitability.
4. Analyze competitive positioning: The biotechnology landscape is dynamic. Investors should assess how Nautilus's technology differentiates itself and its ability to gain market share against competitors.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net loss of $13.574 million and accumulated deficit of $318.2 million. Cash and short-term investments stood at $131.4 million.
• 2024-12-31: End of Fiscal Year 2024 — Cash and short-term investments were $132.826 million. Accumulated deficit was $273.019 million.
• 2025-09-30: End of Nine Months 2025 — Reported net loss of $45.220 million and net cash used in operating activities of $38.321 million.
• 2024-09-30: End of Nine Months 2024 — Reported net loss of $53.186 million and net cash used in operating activities of $44.836 million.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Indicates the company's historical unprofitability, with a current accumulated deficit of $318.2 million as of September 30, 2025.)

Operating lease right-of-use assets

An asset representing the right to use a leased asset for the lease term, recognized under ASC 842. It is typically amortized over the lease term. (These assets decreased from $28.256 million at December 31, 2024, to $24.727 million at September 30, 2025, reflecting lease payments and potential lease terminations.)

Additional paid-in capital

The amount of capital received from investors in exchange for stock that exceeds the par value of the stock. (This account increased from $481.679 million to $487.165 million, suggesting the issuance of new stock or other equity transactions.)

Weighted-average shares used in computing net loss per share

The average number of outstanding shares during a period, adjusted for the timing of share issuances or repurchases, used to calculate earnings or loss per share. (The weighted-average shares increased slightly from 125,452,572 in Q3 2024 to 126,305,122 in Q3 2025, impacting the net loss per share calculation.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Nautilus Biotechnology has shown improvement in reducing its net loss, with Q3 2025 net loss at $13.574 million versus $16.446 million in Q3 2024, and YTD net loss at $45.220 million versus $53.186 million. Total operating expenses also decreased, primarily driven by lower R&D and G&A costs. However, the company's cash position saw a slight decrease, and long-term investments were significantly reduced, while the accumulated deficit continued to grow, albeit at a slower pace.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share NAUT The Nasdaq Stock Market

Filing Documents

• naut-20250930.htm (10-Q) — 1230KB
• exhibit311-q325.htm (EX-31.1) — 10KB
• exhibit312-q325.htm (EX-31.2) — 10KB
• exhibit321-q325.htm (EX-32.1) — 5KB
• exhibit322-q325.htm (EX-32.2) — 5KB
• 0001808805-25-000080.txt ( ) — 5524KB
• naut-20250930.xsd (EX-101.SCH) — 31KB
• naut-20250930_cal.xml (EX-101.CAL) — 57KB
• naut-20250930_def.xml (EX-101.DEF) — 105KB
• naut-20250930_lab.xml (EX-101.LAB) — 471KB
• naut-20250930_pre.xml (EX-101.PRE) — 312KB
• naut-20250930_htm.xml (XML) — 741KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION iii

Financial Statements

Item 1. Financial Statements Condensed Consolidated Financial Statements (Unaudited) iii Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (unaudited) 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 2 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 30

Controls and Procedures

Item 4. Controls and Procedures 31

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 32

Risk Factors

Item 1A. Risk Factors 32

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 78

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 78

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 78

Other Information

Item 5. Other Information 78

Exhibits

Item 6. Exhibits 79

SIGNATURES

SIGNATURES 80 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our management's beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the section entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements include, but are not limited to, statements concerning the following: our dependence on the success of our proteomics platform (the "Nautilus platform"), which remains in the development stage and subject to scientific and technical validation; our expectations regarding the timing and progress of the development of the Nautilus platform and any commercialization timelines; our expectations regarding the functionality of the Nautilus platform; our expectations regarding the availability of private and public research funding for proteomics research and development activities; our estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and needs for additional financing; our expectations regarding the rate and degree of market acceptance of the Nautilus platform; the impact of the Nautilus platform on the field of proteomics and the size and growth of the addressable proteomics market; our ability to manage and grow our business and commercialize our Nautilus platform; our ability to successfully implement our three phase commercial launch plan; the implementation of our business model and strategic plans for the Nautilus platform; our ability to establish and maintain intellectual property protection for our products or avoid or defe

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS iii Nautilus Biotechnology, Inc. Condensed Consolidated Balance Sheets As of September 30, 2025 and December 31, 2024 (Unaudited) (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 23,875 $ 27,646 Short-term investments 107,552 102,247 Prepaid expenses and other current assets 2,898 2,933 Total current assets 134,325 132,826 Property and equipment, net 3,624 4,076 Operating lease right-of-use assets 24,727 28,256 Long-term investments 37,059 76,405 Other long-term assets 1,180 1,180 Total assets $ 200,915 $ 242,743 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 893 $ 987 Accrued expenses and other liabilities 3,880 2,548 Current portion of operating lease liabilities 4,209 4,097 Total current liabilities 8,982 7,632 Operating lease liabilities, net of current portion 22,794 26,381 Total liabilities 31,776 34,013 Commitments and contingencies (Note 8) Stockholders' equity: Preferred stock, $ 0.0001 par value, 200,000,000 authorized as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value, 1,000,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 126,305,122 and 126,106,176 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 13 13 Additional paid-in capital 487,165 481,679 Accumulated other comprehensive income 200 57 Accumulated deficit ( 318,239 ) ( 273,019 ) Total stockholders' equity 169,139 208,730 Total liabilities and stockholders' equity $ 200,915 $ 242,743 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) Three

View Full Filing

View this 10-Q filing on SEC EDGAR